An Open Label, Exploratory, Dose-escalation, Multicenter Study Examining the Safety, Tolerability and Efficacy of Ucb 44212 (Seletracetam) Used at Doses of 10, 20, 40, and 80 mg b.i.d. (Total Daily Doses of 20 - 160 mg) Administration (Oral Capsules) in Adult Subjects (18 - 65 Years) With Refractory Epilepsy Suffering From Partial Onset Seizures Who Are Currently Receiving Levetiracetam (LEV) But Still Experiencing Seizures
Latest Information Update: 12 Sep 2023
Price :
$35 *
At a glance
- Drugs Seletracetam (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors UCB Pharma Inc
- 31 Oct 2023 Primary endpoint has been amended.
- 20 Nov 2005 New trial record.